Lexaria Bioscience Corporation (LEXXW) 뉴스

Interesting that Dr J had a clause put into his compensation should control of the company change...and today more shares for insiders

MORE for mgt--https://s3.amazonaws.com/sec.irpass.cc/2978/0001640334-25-000018.htm

As of the moment MGT has made gains for themselves..,

well taken care of. kind of a pisser to reward before the big gains. like these guys don't make enough already. then we hear the excuses they must be rewarded to attract and keep them on board.

DR John getting taken care of:: SEC FILING --https://s3.amazonaws.com/sec.irpass.cc/2978/0001640334-25-000009.htm. GLTA

https://scitechdaily.com/one-step-closer-to-a-cure-breakthrough-harmine-pill-sparks-hope-for-500-million-diabetics-worldwide/

Special Report: Positive interview with new Lexaria CEO Richard Christopher………….………..…..p 5
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_489f4449167841c7a10795654a27a169.pdf

https://scitechdaily.com/a-new-way-to-treat-obesity-scientists-discover-brain-molecules-that-control-food-cravings/?fbclid=IwY2xjawHVSg5leHRuA2FlbQIxMQABHaWu6OvEsm4A_GJOyL9J0nqeoXv4bteRR64L7x3FVatGhARa91bxwVw80g_aem_gHScQVBUijW8Po92ag6LWQ

Big milestone!! First ever Lexaria clinical study has begun! Great news.

https://mailchi.mp/lexariabioscience.com/lexarias-registered-glp-1-study-4-begins-dosing?e=aa4bd7bcad

8K OUT: https://s3.amazonaws.com/sec.irpass.cc/2978/0001640334-24-001908.htm

https://mailchi.mp/lexariabioscience.com/lexaria-forms-new-scientific-advisory-board?e=aa4bd7bcad

Will Dr. Gibson and Oxford University be involved in the Hypertension trial?
https://www.bidmc.org/research/research-by-department/medicine/cardiovascular-medicine/academic-research-organizations

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Dr. Gibson joining Lexaria's new scientific advisor board

KELOWNA, BC / ACCESSWIRE / December 17, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appointment of Dr. Michael Gibson as its new Chief Medical Advisor. Dr. Gibson will collaborate directly with President John Docherty as Lexaria's patented DehydraTECH drug delivery platform continues to expand its applications in GLP-1 and hypertension.

C. Michael Gibson M.S., M.D., is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School. Gibson founded PERFUSE in 1987 which served as the TIMI Data coordinating center that coordinated data for the first 50 TIMI trials. The Baim institute was formerly known as Harvard Clinical Research Institute and was founded in 2000.

The combined institutes have led over 1,250 studies, published 5,500 manuscripts in peer review literature (including 144 in the New England Journal of Medicine) and have led 70 FDA submissions from their network of 7,000 sites in 57 countries worldwide. Since 2014, Gibson has consistently been ranked as one of the world's most highly cited authors in all of science by Thomson Reuters. In 2021, he was named one of the Fifty of the Most Influential Voices in Healthcare by Medika Life. His work has been cited over 170,000 times.

"Lexaria's drug delivery technology offers exciting new pathways towards improving pharmacokinetic drug performance that could unlock a new era of reduced drug waste and adverse side effects combined with enhanced efficacy," said Dr. Gibson. "I'm excited to pursue new and improved applications for this exciting technology."

"Dr. Gibson has a wealth of knowledge and experience that will benefit Lexaria, particularly in the area of hypertension which remains an area of intense interest for Lexaria," said John Docherty, President. "On behalf of everyone at Lexaria, I welcome Dr. Gibson's contributions as our new Chief Medial Advisor and member of our scientific advisory board."

As Chief Medical Advisor, Dr. Gibson will participate with other scientific and medical experts within Lexaria's newly-formed scientific advisory board in pursuing Lexaria's prioritized objectives in the fields of drug delivery optimization.

Dr. Gibson has led phase 1-4 clinical trials, and cardiology megatrials of over 34,000 patients which eventuate in international approval of drugs like prasugrel, rivaroxaban, betrixaban and andexanet as well as devices such as one that alarms to alert a patient to heart attack. He founded WikiDoc.org and WikiPatient.org and is Editor-In-Chief of over 2,200 active contributors who have edited the content of over 100,000 chapters millions of times over the past 15 years. Gibson also founded www.clinicaltrialresults.org. Gibson serves as Chief Medical Correspondent for the American College of Cardiology. Gibson has over 435,000 followers on social media where he is a leading influencer, second only to Sanjay Gupta in some polls

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

SEC FILING TODAY: https://s3.amazonaws.com/sec.irpass.cc/2978/0001640334-24-001893.htm#a7

Epidiolex(CBD) to be tested for psychosis in clinical trial.
https://www.nature.com/articles/s41591-024-03383-y.epdf?sharing_token=NFA7NDYtTS0ZRsTRHT7ZutRgN0jAjWel9jnR3ZoTv0MVhSv3wC-EELnLsdOkhOVURlkhM34-KkFvGlRWpPdfpsS3QQdX0H5r4ZoGmv7Dyum8hWvkAaFm33y3VChjQwRY0mBbjbpBksYL9CnwoagXDkJmMcuQvsrZp6MtrE2uCFE%3D

https://mailchi.mp/lexariabioscience.com/liraglutide-processed-with-dehydratech-to-be-studied-in-human-glp-1-study-5?e=aa4bd7bcad

https://www.sec.gov/Archives/edgar/data/1348362/000164033424001844/lxrp_424b3.htm

FYI - NEW SEC FILING TODAY FOLKS - CAN NOT GET LINK TO WORK

https://www.msn.com/en-ca/health/other/eli-lilly-says-zepbound-superior-to-wegovy-in-head-to-head-trial/ar-AA1vglK5?ocid=msedgntp&pc=DCTS&cvid=f4ccde60bd4844d38445e34adabd783f&ei=60

Always nice to see insiders acquiring shares on the open market.

All the best,

Knife

CEO PURCHASING SHARES!

https://s3.amazonaws.com/sec.irpass.cc/2978/0001348362-24-000006.htm

LEXX CEO Christopher Richard has purchased a total of 50,000 common shares over yesterday and today. This according to Investing.com.

Lexaria Bioscience: Revolutionizing GLP-1 Drug Delivery with Patented Oral Platform

Special Report: Here’s why Lexaria Bioscience is a hot buy
https://mcusercontent.com/f2e0706764f99154e3a11feb5/files/d0b64069-0fda-38fb-d490-8ba84de7fe94/552Let_039_sTokeBusinessNovember222024.pdf

Lexaria Bioscience: Advancing GLP-1 Drug Delivery with DehydraTECH™ Technology

Lexaria Bioscience: Advancing GLP-1 Drug Delivery with DehydraTECH™ Technology

I SAW 800 PLUS - big chunk of the five $million raise goes to top three execs comp! And what did Bunko do that was well done to deserve it?

Was it around $800k?

10 k is out - Bunko comp WOW

https://mailchi.mp/lexariabioscience.com/revolutionizing-healthcare-lexaria-highlights-expanding-therapeutic-benefits-of-glp-1-drugs?e=aa4bd7bcad

https://mailchi.mp/lexariabioscience.com/lexarias-glp-1-human-pilot-study-3-completes-dosing-as-scheduled?e=aa4bd7bcad

https://mailchi.mp/lexariabioscience.com/all-study-groups-using-dehydratech-processing-outperform-rybelsus-in-body-weight-control?e=aa4bd7bcad

New drugs coming on line that could be improved with DehydraTECH.

https://www.yahoo.com/news/nk2r-side-effect-free-ozempic-163105275.html

https://scitechdaily.com/new-weight-loss-drug-boosts-energy-and-reduces-appetite-without-side-effects/

THEY GET PAID EG DR D $300K A YEAR TO DO R&D WITH OUR MONEY -- BUNKA GETTING $30K A MONTH FOR YEARS -- REWARD WITH NO RISK. UNABLE TO FOCUS ON WHAT WOULD BE SUCCESSFUL AND ATTRACT A PARTNER. DOING MANY RAT STUDIES THAT NO ONE CARES ABO8UT. FILLING BINDERS THAT NO ONE WANTS TO READ. I WANT THEM TO SUCCEED MORE THAN ANYONE - AND MAYBE - JUST MAYBE - THIS NEW CEO CAN STEER THEM TO SUCCESS AND I AT LEAST GET MY MONEY BACK AND THE BOARD MEMBERS HERE CAN RAISE A GLASS TO SUCCESS. GLTU/GLTA

thanks for this explanation Abundance.

It's a study, only it's through a Contract Research Organization as opposed to just using a "plain" Lab. The CRO helps make sure the study is done towards gaining accreditation with clinical trials and FDA whereas a "plain" lab does not. Lexaria will be paying more for this than a "plain" study because of the extra value it will attain but as usual, with all studies, the cost is not announced.

why aren't the terms of this new agreement disclosed? It must not be very good, because of they were good they'd have announced them.

Yeah, why would they want to make massive piles of money being hugely successful when they could fart around all day and potentially go broke?

https://lexariabioscience.com/2024/11/14/lexaria-signs-contract-for-new-dehydratech-glp-1-biodistribution-study/

I have always said that I thought this company would be happy conducting researching on their tech, over focusing on licensing. The endless offerings do not install confidence that a big fish is anywhere close to biting. I read the newest vote/offering as they don't have enough information surrounding the techs (pharma) ability, to hook a fish, so they need the money to just keep doing what they enjoy doing...research. I was hoping the bioscience to pharma rebrand was going to be different, especially in regards to GLP-1's, but I am realizing the pharma was an overstatement. They are really just a research company. Waiting for another OHashi post. Hopefully he has a similar rapport with the new CEO as he did Bunka -- and I assume he does since he has years of investor loyalty to the company.

https://www.sec.gov/Archives/edgar/data/1348362/000164033424001681/lxrp_pre14a.htm

giiant pharma develops gut-restricted, small molecule, tissue-specific drug therapeutics for the treatment of inflammatory bowel diseases (IBD). Precision delivery remains a central focus for the development of new drug therapeutics, with limited systemic exposure for a safer profile while maximizing local action to improve IBD patient care.

https://lexariabioscience.com/2024/11/13/ethics-board-approval-granted-for-lexarias-12-week-phase-1b-dehydratech-glp-1-study-in-diabetes-and-weight-loss/

Updated presentation:
https://lexariabioscience.com/investors/presentations/

https://qz.com/lexaria-bioscience-corp-lexx-quarterly-10-q-report-1851695871

Have a Great Weekend Y'all...🥳